← Back to Search

Radioisotope Therapy

177Lu-DOTATOC for Neuroendocrine Tumors (PUTNET Trial)

Phase 2

Waitlist Available

Led By Ebrahim Delpassand, MD

Research Sponsored by Excel Diagnostics and Nuclear Oncology Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

PUTNET Trial Summary

This trial will test the safety and effectiveness of Lu-177 DOTATOC, given in four doses over eight weeks, for treating adults with certain types of neuroendocrine tumors.

Eligible Conditions

Neuroendocrine Tumors
Pheochromocytoma
Paraganglioma
Thymic Carcinoid
Unknown Primary Tumors
Neuroendocrine Skin Carcinoma
Breast Cancer
Neuroendocrine Carcinoma
Ovarian Neuroendocrine Tumor

PUTNET Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assessment of the overall response rate

Secondary outcome measures

Progression Free Survival (rPFS) in subjects receiving 4 cycles of therapy Monitoring of the changes in quality of life (QOL) through assessment of ECOG performance status and a QOL subject questionnaire.

PUTNET Trial Design

1Treatment groups

Experimental Treatment

Group I: Lu177 DOTATOC treatmentExperimental Treatment1 Intervention

4 doses of 200mCi 177Lu- DOTATOC PRRT

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Excel Diagnostics and Nuclear Oncology CenterLead Sponsor

5 Previous Clinical Trials

663 Total Patients Enrolled

2 Trials studying Neuroendocrine Tumors

312 Patients Enrolled for Neuroendocrine Tumors

Ayman Gaber, MDStudy DirectorExcel Diagnostics and Nuclear Oncology Center

Rodolfo Nunez, MDStudy DirectorExcel Diagnostics and Nuclear Oncology Center

3 Previous Clinical Trials

356 Total Patients Enrolled

1 Trials studying Neuroendocrine Tumors

33 Patients Enrolled for Neuroendocrine Tumors

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What prior investigations have taken place concerning 177Lu-DOTATOC?

"Currently, 30 studies centred around 177Lu-DOTATOC are in progress. Three of these trials are at Phase 3 and operate primarily out of Melbourne, Victoria; though there exist 238 locations researching this treatment worldwide."

Answered by AI

Are researchers currently enrolling participants for this experiment?

"Affirmative. Clinicaltrials.gov documents show that this medical experiment, which was initially advertised on July 30th 2021 is actively seeking participants. Approximately 50 individuals must be recruited from a solitary clinical centre."

Answered by AI

Has 177Lu-DOTATOC been sanctioned by the Federal Drug Administration?

"Since data to support efficacy is still lacking, 177Lu-DOTATOC was given a rating of 2 on the scale due to Phase 2 trial findings which suggest that it may be safe."

Answered by AI

How many volunteers have joined this research endeavor?

"Indeed, the information on clinicaltrials.gov verifies that this medical trial is still recruiting patients. It was originally posted on July 30th 2021 and has been updated as recently as 9th July 2021. The study requires 50 participants to be recruited from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

2020. "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04276597.